AbCellera acquires Trianni for $90M

By The Science Advisory Board staff writers

Artificial intelligence-powered biotech and drug discovery platform AbCellera has purchased Trianni for $90 million. The deal boosts AbCellera's ability to create large human antibody databases for drug discovery.

Trianni develops humanized mice used in drug trials, AbCellera said. Its mice help drug developers investigate multispecific antibodies and immune tolerance as well as target new epitopes.

Adding Trianni to its business expands AbCellera's platform, which currently includes microfluidic single-cell screening, repertoire sequencing, and bispecific protein engineering, according to the firm.

Copyright © 2020

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking